Interestingly, expression of the immune checkpoints PD-1 and CTLA-4 on T cells in CLL patients is markedly downregulated by both ibrutinib and acalabrutinib (Long et al., 2017), suggesting a common BTK-dependent mechanism. The gene discussed is CTLA4; the disease is B-cell chronic lymphocytic leukemia.